BRPI0917099A2 - daa-piridina como ligante do receptor periférico de benzodiazepina para diagnóstico por imagem e tratamento farmacêutico - Google Patents

daa-piridina como ligante do receptor periférico de benzodiazepina para diagnóstico por imagem e tratamento farmacêutico

Info

Publication number
BRPI0917099A2
BRPI0917099A2 BRPI0917099A BRPI0917099A BRPI0917099A2 BR PI0917099 A2 BRPI0917099 A2 BR PI0917099A2 BR PI0917099 A BRPI0917099 A BR PI0917099A BR PI0917099 A BRPI0917099 A BR PI0917099A BR PI0917099 A2 BRPI0917099 A2 BR PI0917099A2
Authority
BR
Brazil
Prior art keywords
daa
pyridine
pharmaceutical treatment
imaging diagnosis
peripheral receptor
Prior art date
Application number
BRPI0917099A
Other languages
English (en)
Inventor
Andrea Thiele
Lutz Lehmann
Sonja Vollmer
Tobias Heinrich
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0917099A2 publication Critical patent/BRPI0917099A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0917099A 2008-08-06 2009-08-05 daa-piridina como ligante do receptor periférico de benzodiazepina para diagnóstico por imagem e tratamento farmacêutico BRPI0917099A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161903 2008-08-06
PCT/EP2009/005651 WO2010015387A1 (en) 2008-08-06 2009-08-05 Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment

Publications (1)

Publication Number Publication Date
BRPI0917099A2 true BRPI0917099A2 (pt) 2016-02-16

Family

ID=41198601

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917099A BRPI0917099A2 (pt) 2008-08-06 2009-08-05 daa-piridina como ligante do receptor periférico de benzodiazepina para diagnóstico por imagem e tratamento farmacêutico

Country Status (24)

Country Link
US (1) US20110200535A1 (pt)
EP (1) EP2321279B1 (pt)
JP (1) JP2011529929A (pt)
KR (1) KR20110041559A (pt)
CN (1) CN102112448B (pt)
AR (1) AR073263A1 (pt)
AU (1) AU2009278279B2 (pt)
BR (1) BRPI0917099A2 (pt)
CA (1) CA2733105A1 (pt)
CL (1) CL2011000237A1 (pt)
CO (1) CO6351715A2 (pt)
CR (1) CR20110064A (pt)
DO (1) DOP2011000046A (pt)
EA (1) EA018650B1 (pt)
EC (1) ECSP11010808A (pt)
IL (1) IL210597A0 (pt)
MX (1) MX2011001406A (pt)
NZ (1) NZ590923A (pt)
PE (1) PE20110226A1 (pt)
SV (1) SV2011003830A (pt)
TW (1) TW201010734A (pt)
UY (1) UY32037A (pt)
WO (2) WO2010015340A1 (pt)
ZA (1) ZA201101700B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177918A1 (en) 2006-12-26 2012-02-28 Lantheus Medical Imaging Inc Ligands for imaging cardiac innervation
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0904715D0 (en) * 2009-03-19 2009-05-06 Ge Healthcare Ltd Aryloxyanilide derivataives
WO2011110488A1 (en) * 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft A novel pet imaging agent of amyloid plaques and its precursor
DK2569019T3 (da) 2010-05-11 2019-12-16 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder og systemer til syntesen og anvendelsen af billeddannelsesmidler
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
AU2012304359B2 (en) 2011-09-09 2016-11-17 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
EP3110424A1 (en) 2014-02-28 2017-01-04 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EP3177147A4 (en) 2014-08-08 2018-01-24 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
SG11201703414VA (en) 2014-10-27 2017-05-30 Tensha Therapeutics Inc Bromodomain inhibitors
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
MX2018003030A (es) 2015-09-11 2018-04-11 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas.
CN114957291A (zh) 2015-11-25 2022-08-30 达纳-法伯癌症研究所股份有限公司 二价溴结构域抑制剂及其用途
CN105541931B (zh) * 2016-01-07 2018-08-17 江西师范大学 一种氟代糖苷衍生物及其制备方法
WO2019105913A1 (en) * 2017-12-01 2019-06-06 Ucb Biopharma Sprl Imaging agents
CN111039853B (zh) * 2019-12-26 2023-02-14 安徽大学 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2299710C (en) * 1997-08-04 2007-11-27 Taisho Pharmaceutical Co., Ltd. Aryloxyaniline derivatives
JP2000001476A (ja) * 1998-06-15 2000-01-07 Taisho Pharmaceut Co Ltd アリールオキシ含窒素アリールアミン誘導体
JP2004231647A (ja) * 2003-01-10 2004-08-19 Natl Inst Of Radiological Sciences フェニルオキシアニリン誘導体
US6870069B2 (en) * 2003-01-10 2005-03-22 National Institute Of Radiological Sciences Phenyloxyaniline derivatives
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
GB0407952D0 (en) * 2004-04-08 2004-05-12 Amersham Plc Fluoridation method
EP1909853B1 (en) * 2005-07-19 2015-03-18 Biosensors International Group, Ltd. Imaging protocols
US20080293969A1 (en) * 2005-11-22 2008-11-27 Ge Healthcare Limited 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors
DE102005055524B4 (de) * 2005-11-22 2013-02-07 BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers
GB0525949D0 (en) * 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
WO2007148088A2 (en) * 2006-06-21 2007-12-27 Ge Healthcare Limited Radiopharmaceutical products
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment

Also Published As

Publication number Publication date
WO2010015340A1 (en) 2010-02-11
WO2010015387A1 (en) 2010-02-11
EP2321279A1 (en) 2011-05-18
IL210597A0 (en) 2011-03-31
AU2009278279B2 (en) 2014-04-17
DOP2011000046A (es) 2011-02-28
KR20110041559A (ko) 2011-04-21
PE20110226A1 (es) 2011-04-01
EA018650B1 (ru) 2013-09-30
TW201010734A (en) 2010-03-16
EP2321279B1 (en) 2014-07-02
ECSP11010808A (es) 2011-03-31
CN102112448A (zh) 2011-06-29
CL2011000237A1 (es) 2011-07-29
AR073263A1 (es) 2010-10-28
EA201100301A1 (ru) 2011-12-30
US20110200535A1 (en) 2011-08-18
CO6351715A2 (es) 2011-12-20
CR20110064A (es) 2011-03-30
JP2011529929A (ja) 2011-12-15
CN102112448B (zh) 2014-08-06
CA2733105A1 (en) 2010-02-11
AU2009278279A1 (en) 2010-02-11
SV2011003830A (es) 2011-05-20
UY32037A (es) 2010-03-26
MX2011001406A (es) 2011-03-21
NZ590923A (en) 2012-12-21
ZA201101700B (en) 2014-08-27

Similar Documents

Publication Publication Date Title
BRPI0917099A2 (pt) daa-piridina como ligante do receptor periférico de benzodiazepina para diagnóstico por imagem e tratamento farmacêutico
EP2473147A4 (en) AIR CONDITIONING FASTENER FOR MEDICAL BEDS
EP2119444A4 (en) THERAPEUTIC AGENT FOR PAIN
BRPI0917549A2 (pt) dispositivo para a liberação de um medicamento
BRPI0814624A2 (pt) Tratamento de doença neurodegenerativa progresiva com ibudilaste
BR112012009021A2 (pt) dispositivo de cuidados para tecidos
IL211320A (en) Tet system for implanted medical device
EP2196137A4 (en) MEDICAL DIAGNOSTIC SUPPORT SYSTEM
ZA201204213B (en) Neutralizing prolacting receptor antibodies and their therapeutic use
PL3058875T3 (pl) System do zabiegu kosmetycznego i obrazowania
BR112012004178A2 (pt) implemento para cuidado oral, e, aparelho para um implemento oral
BR112012001819A2 (pt) métodos para tratamento de dor
FI20145006A (fi) Röntgen-TT-kuvauslaite
EP2284519A4 (en) BIOLOGICAL IMAGING DEVICE
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI1012578A2 (pt) conjunto para um dispositivo para distribuição de fármaco e dispositivo para distribuição de fármaco
DE602008002134D1 (de) Prozesskartusche und Bilderzeugungsvorrichtung
EP3431085C0 (en) Selective ep4 receptor antagonistic substance for treatment of cancer
ZA201204845B (en) Agents for treating disease
BRPI0922423A2 (pt) dispositivo de liberação de fármaco
BRPI0913033A2 (pt) projeto de pad para mram-stt
BRPI1008706A2 (pt) dispositivo para diagnóstico.
EP2465512A4 (en) PAIN-SUBJECTIVE PHARMACEUTICAL COMPOSITION
BR112013009861A2 (pt) compostos para uso em imagem, diagnóstico e/ou tratamento de doenças do sistema nervoso central
EP2222689A4 (en) THERAPEUTIC AND DIAGNOSTIC COMPOUNDS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2376 DE 19-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.